Pila Pharma AB (PILA) - Total Liabilities
Based on the latest financial reports, Pila Pharma AB (PILA) has total liabilities worth Skr1.43 Million SEK (≈ $154.32K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pila Pharma AB - Total Liabilities Trend (2015–2025)
This chart illustrates how Pila Pharma AB's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Pila Pharma AB's working capital to evaluate short-term liquidity relative to the company's equity base.
Pila Pharma AB Competitors by Total Liabilities
The table below lists competitors of Pila Pharma AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hemostemix Inc
V:HEM
|
Canada | CA$4.80 Million |
|
Sipa Resources Ltd
AU:SRI
|
Australia | AU$540.56K |
|
Hays plc
LSE:HAS
|
UK | GBX1.30 Billion |
|
Home Pottery Public Company Limited
BK:HPT
|
Thailand | ฿93.80 Million |
|
FOS Capital Ltd
AU:FOS
|
Australia | AU$10.52 Million |
|
Strategic Energy Resources Ltd
AU:SER
|
Australia | AU$1.16 Million |
|
Sahakol Equipment Public Company Limited
BK:SQ
|
Thailand | ฿5.61 Billion |
|
MEDAPP S.A. ZY -10
F:WQ1
|
Germany | €13.06 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Pila Pharma AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PILA market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pila Pharma AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pila Pharma AB (2015–2025)
The table below shows the annual total liabilities of Pila Pharma AB from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr1.43 Million ≈ $154.32K |
+48.91% |
| 2024-12-31 | Skr963.00K ≈ $103.63K |
-46.33% |
| 2023-12-31 | Skr1.79 Million ≈ $193.09K |
+32.22% |
| 2022-12-31 | Skr1.36 Million ≈ $146.03K |
-10.42% |
| 2021-12-31 | Skr1.51 Million ≈ $163.01K |
-22.20% |
| 2020-12-31 | Skr1.95 Million ≈ $209.53K |
+301.72% |
| 2019-12-31 | Skr484.68K ≈ $52.16K |
-41.04% |
| 2018-12-31 | Skr821.98K ≈ $88.46K |
+46.42% |
| 2017-12-31 | Skr561.37K ≈ $60.41K |
-12.93% |
| 2016-12-31 | Skr644.76K ≈ $69.39K |
+162.19% |
| 2015-12-31 | Skr245.91K ≈ $26.46K |
-- |
About Pila Pharma AB
Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases. Pila Pharma AB (publ) was incorporated in 2014 and is hea… Read more